Search results
Results from the WOW.Com Content Network
[54] [55] The $875 million settlement broke down to $290 million for violating the Prescription Drug Marketing Act, $559.5 million to settle federal fraud charges for overcharging Medicare, and $25.5 million reimbursement to 50 states and Washington, D.C., for filing false claims with the states' Medicaid programs. [55]
[3] [4] It is a decapeptide (pGlu-His-Trp-Ser-Tyr- D -Trp-Leu-Arg-Pro-Gly-NH 2 ) and a gonadotropin-releasing hormone agonist (GnRH agonist) used as the acetate or pamoate salts . Primary indications include endometriosis , [ 5 ] for the reduction of uterine fibroids , to treat prostate cancer , and to treat male hypersexuality with severe ...
Cyproterone acetate (CPA), sold alone under the brand name Androcur or with ethinylestradiol under the brand names Diane or Diane-35 among others, is an antiandrogen and progestin medication used in the treatment of androgen-dependent conditions such as acne, excessive body hair growth, early puberty, and prostate cancer, as a component of feminizing hormone therapy for transgender individuals ...
Levomepromazine, also known as methotrimeprazine, is a phenothiazine neuroleptic drug.Brand names include Nozinan, Levoprome, Detenler, Hirnamin, Levotomin and Neurocil. It is a low-potency antipsychotic (approximately half as potent as chlorpromazine) with strong analgesic, hypnotic and antiemetic properties that are primarily used in palliative care.
50–250 mg 1x/1–4 weeks Xyosted: Auto-injector: 50–100 mg 1×/week Testosterone cypionate: Depo-Testosterone: Oil solution: 50–250 mg 1x/1–4 weeks Testosterone isobutyrate: Agovirin Depot: Aqueous suspension: 50–100 mg 1x/1–2 weeks Testosterone phenylacetate b: Perandren, Androject: Oil solution: 50–200 mg 1×/3–5 weeks Mixed ...
Chlormadinone acetate (CMA), sold under the brand names Belara, Gynorelle, Lutéran, and Prostal among others, is a progestin and antiandrogen medication which is used in birth control pills to prevent pregnancy, as a component of menopausal hormone therapy, in the treatment of gynecological disorders, and in the treatment of androgen-dependent conditions like enlarged prostate and prostate ...
[39] [40] It is available in 50 mg, 80 mg (in Japan), [48] and 150 mg tablets for oral administration. [ 82 ] [ 83 ] The drug is registered for use as a 150 mg/day monotherapy for the treatment of LAPC in at least 55 countries, [ 2 ] with the U.S. being a notable exception where it is registered only for use at a dosage of 50 mg/day in ...
On 14 January 2016, the European Commission, [11] and on 18 February 2016, the U.S. Food and Drug Administration (FDA) [23] approved brivaracetam under the trade name Briviact. The Drug Enforcement Administration (DEA) issued an interim final rule [ clarification needed ] placing brivaracetam into schedule V of the Controlled Substances Act ...